Article

Discovery and preliminary validation of a new panel of personalized ovarian cancer biomarkers for individualized detection of recurrence

2023-11-23

Abstract excerpt

<h4>Background: </h4> Following first-line treatment, over 80% of advanced ovarian cancer cases suffer recurrence. Treatment of patients with recurrence based on CA125 has not resulted in improvements in outcome postulating that we need biomarkers for earlier detection. A tumor-specific array of serum proteins with advanced proteomic methods could identify personalized marker signatures that detect relapse at a po...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 60273172-f353-5db9-83cf-15da5d62e576
DOI: 10.12688/f1000research.140640.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery and preliminary validation of a new panel of personalized ovarian cancer biomarkers for individualized detection of recurrenceDOI 10.12688/f1000research.140640.1Read

High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancerSemantic proximity Read

Proteomic landscape of epithelial ovarian cancer.Semantic proximity Read

An overview of biomarkers for the ovarian cancer diagnosis.Semantic proximity Read

Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancerSemantic proximity Read

A multiplex platform for the identification of ovarian cancer biomarkersSemantic proximity Read

Multi-biomarker panel signature as the key to diagnosis of ovarian cancerSemantic proximity Read

Applications of Proteomics in Ovarian Cancer: Dawn of a New EraSemantic proximity Read

Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detectionSemantic proximity Read

Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profilingSemantic proximity Read

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenograftsSemantic proximity Read

Integrated analysis of tumor and adjacent non-tumor proteomic data reveals SERPINH1 as a recurrence biomarker and drug target in hepatocellular carcinomaSemantic proximity Read

Plasma protein and tumor tissue gene expression analyses in ovarian cancer reveals differentially co-regulated clusters between benign and malignant conditionsSemantic proximity Read